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INTRODUCTION
Cancer therapies have evolved and improved quite significantly 
over the years. Most available drug therapies effect cancer kill by 
interfering with the replicative and signalling processes necessary 
for cell proliferation and survival. These changes are however, 
unfortunately not limited to cancer cells only, as muscle, including 
cardiac muscle, bone marrow and the nervous system are potential 
bystanders which can be negatively affected by cancer therapies.
The commonest drugs known to have cardiotoxic effects include 
anthracyclines, monoclonal antibodies (such as trastuzumab and 
bevacizumab), and recently the tyrosine kinase inhibitors which 
are utilised in the treatment of metastatic renal cell carcinoma, 
gastrointestinal stromal tumours and pancreatic neuro endocrine 
tumours.
Other drugs like taxanes and fluoropyrimidines and some alkyla-
ting agents also have cardiotoxic effects, via largely unknown 
mechanisms. 
CHEMOTHERAPY DRUGS
Anthracyclines
Anthracyclines have long been in use for various cancers including 
breast cancer, lymphoproliferative disorders, sarcomas and some 
gastrointestinal cancers among others. Their mechanisms of action 
The treatment options for patients with cancer have increased 
rapidly in the last decade with the introduction of newer 
chemotherapy drugs, targeted agents and monoclonal anti-
bodies. Most of these drugs are aimed at interrupting pro-
liferative signalling, with consequent apoptosis of cancer cells.
Because most of the new drugs are multi-targeted, there is a 
likelihood of so called “off target” effects, where other kinases 
which are not the primary targets of the drug, are also 
inhibited. This has led to unforeseen toxicities and, in this 
commentary, we will focus on the molecular mechanisms 
underlying cardiotoxicities as a result of cancer therapies.
However, cardiotoxicity is not a new concern as the older 
generation chemotherapies, like anthracyclines, are known to 
commonly cause irreversible cardiomyopathy, mostly as a 
result of induced DNA damage and oxidative stress. Over the 
years, clinicians have adopted some methods of diminishing 
the incidence of this side-effect and therefore improving 
patient safety.
Trying to decipher the complicated pathways underlying 
cardiotoxicity helps the scientifi c community to design new 
drugs that are tumoricidal, whilst sparing normal tissue and as 
such limiting unwanted side-effects. This has become ever so 
important, as oncologists cure more patients of cancer, and 
some previously incurable cancers are increasingly being 
converted into chronic illnesses. A relationship between the 
cardiologist and the oncologist has become mandatory to 
ensure close monitoring of such patients and offering appro-
priate management, should cardiotoxicities arise.
SAHeart 2012; 9:244-248
TABLE 1: Cardiovascular toxicity of anti-cancer drugs
Toxicity  Drugs 
Congestive heart failure Anthracyclines
 Some alkylating agents (e.g. cyclophosphamide) 
 Monoclonal antibodies (e.g. trastuzumab) 
 Tyrosine kinase inhibitors
Ischaemic/Thrombo-embolism 5 Fluoropyrimidines  (e.g. 5 fl uorouracil)
 Taxanes (e.g. paclitaxel, docetaxel)
 Platinum compounds (e.g. cisplatin)
Hypertension Monoclonal antibodies (e.g. bevacizumab) 
  Tyrosine kinase inhibitors (e.g. sunitinib,  
sorafenib) 
Brady arrhythmias  Taxanes
QT prolongation Tyrosine kinase inhibitors (e.g. nilotinib)
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include interfering with DNA cross-linking, release of free radicals, 
and inhibition of both DNA replication and RNA transcription 
amongst others.(1) Tissues with rapidly dividing cells are most at 
risk for acute or late toxicities, but most of these resolve over time 
as new cell regeneration occurs when the offending therapy stops.
The cardiac muscle however, has limited regenerative potential, 
and this may account for the cardiotoxicity seen, particularly with 
this class of agents.
The early clinical studies involving anthracyclines did not show 
significant cardiotoxicity due to limited duration of exposure to the 
drug, largely on the basis of dose limiting myelosupression. 
However, with improved supportive care and subsequent 
prolonged use of these drugs in clinical practice, it has emerged that 
anthracyclines have a cumulative toxicity on the myocardium, which 
rises significantly beyond 550mg/m2 for doxorubicin and 900mg/m2 
for epirubicin.(2) 
Cardiotoxicity of anthracyclines is thought to be mediated by other 
mechanisms excluding those responsible for tumour cell kill, and 
this suggests that mechanisms countering this toxicity can be found 
without interfering with drug efficacy.
Anthracyclines induce myocyte damage and cell death via necrosis 
and apoptosis. Endomyocardial biopsies performed in patients 
following anthracycline exposure have shown mitochondrial 
swelling and chromatin contraction which are cardinal features 
of apoptotic cell death. Myocyte damage following these drugs 
is concentration dependant; with apoptosis likely to happen at 
lower doses of exposure, and necrosis at higher doses.
Another major mechanism of action of anthracyclines is release of 
oxygen free radicals, and an increase in oxidative stress leading 
to lipid peroxidation, vacuolation and fibrosis.(3) Anthracyclines are 
also associated with a decrease in the release of endogenous 
enzymes, like glutathione peroxidase which role is to scavenge 
free radicals.(4,5)
Release of reactive oxygen species may trigger apoptosis by 
cytochrome C and caspase C release, resulting in myocyte death.(6)
The DNA damage induced by anthracyclines may act as another 
trigger for apoptosis. Among the numerous other mechanisms of 
action of the anthracyclines, is intercalation of base pairs, which 
inhibits DNA and RNA synthesis.(7) It is this very mechanism that 
leads to cumulative cardiotoxicity on the basis of accumulation of 
DNA mutations.
Sarcomere disruption has also been shown on endomyocardial 
biopsies of patients following anthracycline exposure. The changes 
include loss of myofibrils and dilation of the sarcoplasmic reticu-
lum.(8) The breakdown of titin, a giant myofilament protein and a 
part of the sarcomere in striated muscle, is one of the early events 
in sarcomeric disruption. In addition to this, anthracyclines also 
suppress sarcomeric protein synthesis, leading to what Sawyer, 
et al. have coined “cardiac sarcopenia”.(9)
Fluoropyrimidines 
5 Fluorouracil (5FU) is the most common 5 fluoropyrimidine (a 
pyrimidine antimetabolite), used in the treatment of various cancers 
including colon, gastric, and head and neck cancers. It has been 
demonstrated to have a small, but real risk of cardiac toxicity, 
mainly in the form of arrhythmias and coronary vasospasm. The 
mechanism of its cardiotoxicity is unclear, but it is thought to be 
due to vascular spasm secondary to the breakdown products of 5 
FU namely fluoro beta-alanine and fluoro acetate. 5 Fluorouracil’s 
most common cardiotoxic effect is angina like chest pain and 
ischaemic ECG changes. The possible mechanisms of cardiotoxicity 
are coronary artery thrombosis, interaction with the coagulation 
system, vasospasm and direct myocardial toxicity. On electron 
microscopy the changes that occur following 5FU toxicity are seen 
in the endothelium of the small vessels.(10) Myocarditis has also been 
demonstrated in some autopsy results.(11)  
Other potential cardiotoxic drugs
Other drugs including alkylating agents, like cyclophosphamide 
when administered at high doses are also potentially cardiotoxic, 
though the actual mechanisms of cardiotoxicity are largely unknown. 
The platinum compounds cisplatin and carboplatin have also shown 
to increase the risk of thrombolic events but no specific cardio-
toxicity increase has been documented. The cardiotoxicity of 
cisplatin is thought to be related to the electrolyte imbalances that 
can occur with cisplatin-induced nephrotoxicity.
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other results suggest that erb 2 is essential in cardiac development 
and function, and that inhibition thereof by trastuzumab is central 
to the cardiotoxicity of the drug. However, it is unlikely to be this 
simple, since lapatinib, a dual inhibitor of erb 2 and EGFR has 
minimal cardiotoxicity, demonstrating that this is unlikely to be the 
only mechanism.
In addition, it has been postulated that previous use of anthra-
cyclines heightens the risk of trastuzumab-related cardiac dys-
function. Erb 2 signalling also plays a role in regulating sarcomeric 
structure and inhibition thereof, and accelerates the sarcomeric 
breakdown that has been previously mentioned in relation to 
anthracyclines.
Vascular Endothelial Growth Factor Receptor (VEGFR) 
inhibitors: bevacizumab
Bevacizumab is an anti-angiogenic drug, a monoclonal antibody 
against VEGFR. It is effective against a number of cancers including 
colon, ovarian, lung and renal cell carcinoma. One of the com-
monest reported side-effects is hypertension, reported to be as 
high as 23% in some studies.(19) This is in part due to decreased 
nitric oxide production, which leads to vasoconstriction and an 
increase in blood pressure. There is also evidence of remodelling 
of the capillary beds, a process known as capillary rarefaction, in 
patients exposed to these specific agents. A reduction in the mean 
dermal capillary density as well as a decreased vasodilatory response 
was found on skin biopsies performed in patients receiving 
bevacizumab.(20) As with many other cancer therapies, apoptosis 
has also been implicated in endothelial cells of patients receiving 
anti-angiogenic drugs.(21)
Multi-targeted tyrosine kinase inhibitors: sorafenib, sunitinib 
and other small molecules
One of the many advances in cancer therapy has been the 
development of small molecule tyrosine kinase inhibitors for the 
treatment of various cancers, including renal cell carcinoma, gastro-
intestinal stromal tumours (GIST) and chronic myeloid leukaemia 
(CML). These drugs inhibit multiple tyrosine kinases that drive 
cellular proliferation. The use of these agents has yielded significant 
disease-free and overall survival benefits among patients with the 
different cancers for which they are currently in use.
The potential downside however is the so-called “off-target” effect, 
resulting in the inhibition of other tyrosine kinases that are not 
Taxanes (originally derived and synthesised from the American and 
European yew tree) can induce a large spectrum of cardiac distur-
bances of a varied aetiology. Some of the documented arrhythmias 
have been attributed to the use of the solvent cremophor.  
Taxanes cause mainly bradycardia and a dilated cardiomyopathy, 
especially when used in combination with anthracyclines. In some 
series, the incidence of cardiotoxicity has been as high as 20% 
when the drugs were used in combination.(12) The cardiotoxicity of 
taxanes is thought to be related to the drug's structural similarity to 
the yew taxine, a known cardiotoxic alkaloidal. 
MONOCLONAL ANTIBODIES AND TARGETED 
THERAPIES
Anti Her 2 receptor drugs: trastuzumab
Trastuzumab is a humanised monoclonal antibody against erb 2 
receptor tyrosine kinase, a member of the Endothelial Growth 
Factor Receptor (EGFR) family. Erb 2 is over-expressed in 20 to 
30% of all breast cancers, and patients whose cancers over-
express erb 2 have a higher risk of disease recurrence, distant 
spread and decreased survival. The addition of trastuzumab to 
chemotherapy, both in the adjuvant and metastatic settings have 
yielded improvements in disease-free survival and overall survival.
(13-15) However, cardiotoxicity has been noted as a side-effect in 
numerous clinical trials, and is more pronounced in patients who 
have received an anthracycline. Cardiotoxicity ranges from 3 to 7% 
when trastuzumab is administered as a single agent, and up to 27% 
when administered concurrently with an anthracycline.(16)
The mechanisms underlying trastuzumab-related cardiotoxicity are 
not completely understood. It causes contractile dysfunction that 
does not, unlike anthracycline-mediated cardiotoxicity, appear to 
be dose-related. The cardiotoxicity of trastuzumab also is revers-
ible in some cases, even allowing for re-challenging with the drug 
if the benefit is felt to outweigh the risks in individual patients. 
Erb 2 plays a major role in embryonic cardiomyocyte develop-
ment and function. This is evidenced by the fact that germline 
deletions of erb 2, erb 4 and neuregulin 1 in mice are lethal in mid-
gestation due to failure of ventricles to form properly.(17) Neuregulin 
is a peptide ligand of erb 2 and erb 4 and is produced by cardiac 
endothelial cells. By binding to erb 4 it causes heterodimerisation 
of erb 2 and erb 4, leading to autophosphorylation of the hetero-
dimer and inducing downstream signalling pathways.(18) These and 
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the primary target of the drug, as these drugs are able to inhibit 
between 15 to 50 kinases at a time.(22) Sorafenib, for instance, 
targets VEGFR 2/3, RAF 1,c-kit, PDGFR and FLT 3 amongst others. 
Such wide effect may lead to the inhibition of other unknown 
kinases which might be responsible for ventricular function. This 
may lead to unforeseen cardiac toxicities. For example, in an 
animal model, RAF 1 deletion led to mitochondrial dysfunction and 
a myopathic heart.(23) RAF inhibits proapoptotic kinases, ASK 1 and 
MST 2, and inhibition of RAF thus leads to accelerated apoptosis 
in selected tissues. 
Chintalgattu, et al., have highlighted the importance of PDGFR in 
the tolerance of the heart to afterload stress. Mice with a deletion 
of the PDGFR ß gene, with no changes at baseline, developed 
ventricular dilatation and cardiac failure when exposed to afterload 
stress.(24)
They further proposed a two-hit hypothesis of cardiotoxicity with 
sunitinib; a tyrosine kinase inhibitor used for the treatment of renal 
cell carcinoma and relapsed GIST. The first hit would be an increase 
in blood pressure, followed by PDGFR inhibition which leads to 
inability of the cardiac muscle to handle this increase in afterload, 
with the second hit leading to cardiac failure.
Other investigators have found evidence of mitochondrial damage 
in relation to treatment with tyrosine kinase inhibitors, and 
cardiomyocytes treated with these agents demonstrated a loss 
of mitochondrial action potential and a subsequent decrease in 
ATP.(25)
Cardiac toxic effects of tyrosine kinase inhibitors range from 
electrocardiographic changes (QT segment prolongation), a drop in 
the left ventricle ejection fraction measured by echocardiography 
or MUGA, to congestive heart failure, and coronary and myo-
cardial events.
Sunitinib possibly exerts its cardiotoxicity through the inhibition 
of PDGF receptors, promoting  apoptosis. Sorafenib does it by 
inhibiting RAF 1. Deletion of its gene in the heart leads to an 
increased cardiomyocite apoptotic event.(26-27)
Many other potential mechanisms have been postulated, mainly 
around enhanced apoptosis, and inhibition of anti-apoptotic pro-
teins. However, some of those mechanisms by which these drugs 
cause cardiotoxicity remains unclear.
CONCLUSION
Cardiotoxicity remains an important concern in cancer care, since
it has the potential to reverse the gains made by improved 
cancer treatment and the discovery of new drugs. The mechanisms 
of toxicity are not always clear, and there is ongoing work to better 
elucidate them. Traditional chemotherapy targets rapidly dividing 
cells (which are not all malignant). New targeted therapies available 
for the treatment of cancer patients are tailored to the specific 
genetic changes expressed by each cancer type. Cardiovascular 
effects of chemotherapy are numerous, different and range from a 
decrease in myocardial contractility (anthracyclines), increased 
ischaemic changes (fluoropyrimidines) to those drugs that can affect 
the conduction system resulting in arrhythmias or blocks (alkylating 
agents, taxanes). Cardiovascular effects of targeted therapies are 
also varied and include heart failure, conduction abnormalities, QT 
prolongation, hypertension and myocardial injury, although systolic 
dysfunction  – which leads to heart failure – is the most common 
side effect. This is as a result of the fact that those pathways involved 
in the survival and proliferation of cancer cells can also impact on 
the survival of non-malignant cells, such as normal cardiomyocytes. 
Targeting those pathways with the new available molecules, may 
also produce cardiotoxic effects, mainly cardiomyopathy due to the 
inhibition of the same kinases in the normal cardiomyocytes. Further 
understanding of these multiple mechanisms will assist in the 
development of safer drugs without compromising tumoricidal 
activity. It will also aid oncologists to improve patient selection, 
diagnose toxicities early and refer patients timeously to cardiologists. 
It will enable improved methods of mitigating the risk with stringent 
monitoring, thereby increasing the levels of patient safety. Albini 
and others have stressed the need to develop guidelines that 
include the effects on the cardiovascular system. They have 
recommended the creation of the new interdisciplinary field of 
cardio-oncology, where oncologists and cardiologists can work 
together in an effort to avoid or prevent adverse cardiac effects 
while patients with cancer are receiving chemotherapy.(28) The 
relationship between the oncologist and the cardiologist cannot be 
over-emphasised, as we continue to seek ways to deliver safe and 
effective cancer care to our patients within a multidisciplinary 
context.
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